RCS - Physiomics PLC - Contract award

PhysiomicsAnnouncement

10/11/2022 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221110:nRSJ9790Fa&default-theme=true

RNS Number : 9790F  Physiomics PLC  10 November 2022

10 November 2022

 

Physiomics plc

("Physiomics") or ("the Company")

 

Contract award

 

Physiomics plc (AIM: PYC), the consultancy using mathematical models to
support the development of drug treatment regimens and personalised medicine
solutions, is pleased to announce that it has been awarded a further contract
by existing client Ankyra Therapeutics ("Ankyra"). Building on the work that
was announced in March this year, this contract extension is expected to
complete in the first quarter of 2023.

 

Ankyra is a Boston-based biotech company focused on improving both the safety
and efficacy of cancer treatment by using their proprietary anchored
immunotherapy platform. Ankyra announced a successful US$45 million Series B
funding round a year ago to finance its lead molecule ANK-101 through Phase 1
clinical trials and has an emerging pipeline of additional immunotherapy-based
programs. Physiomics is supporting Ankyra with the modelling and simulation of
ANK-101 in immune-oncology settings in support of its early development and
clinical translation.

 

Physiomics CEO, Dr Jim Millen, commented: "We are delighted to continue
supporting Ankyra Therapeutics for the development of this exciting new
molecule ANK-101 through the use of modelling and simulation."

 

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPGRCGUPPURU